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                                                   Abstract 
 
There is renewed interest in magnetic hyperthermia as a treatment modality for cancer, 
especially when it is combined with other more traditional therapeutic approaches, such as the 
co-delivery of anticancer drugs or photodynamic therapy. The influence of bimagnetic 
nanoparticles (MNPs) combined with short external alternating magnetic field (AMF) exposure 
on the growth of subcutaneous mouse melanomas (B16-F10) was evaluated.  Bimagnetic 
Fe/Fe3O4 core/shell nanoparticles were designed for cancer targeting after intratumoral or 
intravenous administration.  Their inorganic center was protected against rapid biocorrosion by 
organic dopamine-oligoethylene glycol ligands. TCPP (4-tetracarboxyphenyl porphyrin) units 
were attached to the dopamine-oligoethylene glycol ligands. The magnetic hyperthermia results 
obtained after intratumoral injection indicated that micromolar concentrations of iron given 
within the modified core-shell Fe/Fe3O4 nanoparticles caused a significant anti-tumor effect on 
murine B16-F10 melanoma with three short 10-minute AMF exposures. There is a decrease in 
tumor size after intravenous administration of the MNPs followed by three consecutive days of 
AMF exposure.  These results indicate that intratumoral administration of surface-modified 
MNPs can attenuate mouse melanoma after AMF exposure.  Moreover, intravenous 
administration of these MNPs followed by AMF exposure attenuates melanomas, indicating that 
adequate amounts of TCPP-labeled stealth Fe/Fe3O4 nanoparticles can accumulate in murine 
melanoma after systemic delivery to allow effective magnetic hyperthermic therapy in a rodent 
tumor mode 
 iv 
    Table of Contents 
List of Figures ........................................................................................................................... vi 
Acknowledgements ................................................................................................................. viii 
CHAPTER 1- Background- Melanoma, Magnetic Hyperthermia & Porphyrine tethered stealth 
coated Iron/Iron oxide core/shell Magnetic Nanoparticles………………………………………… 
………………………………………………………………………………………………1 
    Melanoma………………………………………………………………………………………2 
    Hyperthermia…………………………………………………………………………………...4 
    Magnetic Hyperthermia………………………………………………………………………...6    
    Porphyrine tethered stealth coated Iron/Iron oxide core/shell Magnetic Nanoparticles……….8 
CHAPTER 2- Porphyrin tethered stealth coated MNP- in vitro studies on B16-F10 melanoma   
  cells……………………………………………………………………………………………..10 
Materials & Methods………………………………………………………………………….10 
Cell lines…………………………………………………………………………………10 
Porphyrin tethered Stealth-Coated (Bi) Magnetic Fe/Fe3O4 Nanoparticles…………… .10 
Determination of iron concentration in MNPs…………………………………………...11 
Cytotoxicity of Magnetic Nanoparticles on B16-F10 cells……………………………...11 
Prussian blue staining on MNP treated cells…………………………………………….12 
Statistical analysis………………………………………………………………………..12 
     Results and discussion………………………………………………………………………..12 
 Figures………………………………………………………………………………………..14 
CHAPTER-3- Porphyrin tethered stealth coated MNP- in vivo studies    on B16-F10 mouse 
subcutaneous mealnoma model………………………………………………………………….15 
     Materials & Methods…………………………………………………………………………15 
             Cell lines & Animals…………………………………………………………………….15 
             Porphyrin tethered Stealth-Coated (Bi) Magnetic Fe/Fe3O4 Nanoparticles…………….15 
             Magnetic Heating………………………………………………………………………..16 
             Temperature measurements on mice……………………………………………………16 
             Intratumoral Hyperthermia……………………………………………………………...17 
             Intravenous administration of MNPs with AMF exposure……………………………..17 
 v 
            Histological Analysis…………………………………………………………………….18 
            Statistical analysis……………………………………………………………………….18 
      Results ………………………………………………………………………………………19 
            Temperature measurements on mice after intramuscular MNP injection……………….19 
            Intratumoral Magnetic Hyperthermia……………………………………………………19 
            Intravenously administered MNPs and AMF exposure………………………………….19 
            Apoptosis assay…………………………………………………………………………..20 
     Discussion…………………………………………………………………………………….21 
Figures………………………………………………………………………………………...24 
References………………………………………………………………………………………..30 
 
 vi 
 
    List of Figures 
Figure 2.1 In vitro cell viability of B16-F10’s cultured in medium containing increasing 
concentrations of MNPs, as measured by iron concentration. *Statistically significant (p-value 
less than 0.05;two tail ANOVA)………………………………………………………………13 
Figure 2.2 B16-F10 cells after overnight incubation with TCPP labeled MNP. A: control B16-
F10 cells (without MNP); B: B16-F10 cells incubated with MNP, C:MNP-incubated B16-F10 
cells after Prussian blue staining…………………………………………………………………14 
Figure 3.1 Graph depicting temperature change at MNP injection site and in body core during 
AMF exposure, measured with a fiber optic temperature probe………………………………24 
Figure 3.2 Effect on tumor burden of intratumoral injection of MNPs followed by AMF 
treatments.  Graph depicting average B16-F10 tumor volumes over time in mice which were 
later injected with either saline or MNPs intratumorally and with or without AMF treatments.  
*Statistically significant (p-value less than 0.1)…………………………………………………25 
Figure 3.3 Tumor volume comparison of intravenous MNP administration and AMF exposure 
group with intravenous DMEM (placebo) and intravenous MNP without AMF exposure groups 
on day 14 and day 18. (not statistically significant)……………………………………………26 
Figure 3.4 Effect of intravenous injection of MNP and AMF on tumor weight.  *Statistically 
significant (p-value less than 0.1)- between control and IV MNP+AMF groups………………27 
Figure 3.5 Prussian blue staining on tissue sections after the in vivo experiment.  A-C: IV MNP 
+ AMF in tumor, lung, and liver, respectively D: IT MNP+AMF tumor (Scale bar =100 
μm)……………………………………………………………………………………………28 
 vii 
Figure 3.6 Green fluorescence indicates apoptosis positive and blue is DAPI counterstaining. E-
G: Apoptosis assay pictures.  E: Control tumor section.  F: Tumor section with intravenous MNP 
administration followed by AMF.  G: Tumor section with intratumoral MNP administration 
followed by AMF.  (Scale bar =100 μm)……………………………………………………29 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
     Acknowledgements 
I would like acknowledge my major professor, Dr. Deryl L.Troyer, for giving me the 
opportunity to work in his lab for my masters degree. I would like acknowledge my committee 
members, Dr. Stefan Bossmann and Dr. Viktor Chikan, for their valuable input for my degree 
program and in my thesis. I would like to thank my lab members, Marla Pyle, Dr.Rajashekar 
Rachakatla, and Dr. Gwi-Moon Seo, for their help in my project and proofreading of my thesis. I 
would also like to thank members of Dr. Bossmann’s,, Dr.Chikan’s and Dr.Tamura’s labs, 
Hongwang, Thilani Samarakoon, Raj Dani, and Dr. Atsushi Kawabata, for their help in my 
project.  
 
 1 
 
CHAPTER 1 - Melanoma, Magnetic Hyperthermia & Porphyrine 
tethered stealth coated Iron/Iron oxide core/shell Magnetic 
Nanoparticles 
Recently, questions have surfaced about whether anticancer drug development is headed 
in the right direction and whether opportunities off the accepted path are being overlooked. [1] 
Largely due to increasing insight into the series of mutations associated with the development of 
cancer, drug development has moved into the “molecular target” area.  There have been initial 
successes (e.g. imatinib mesylate for the treatment of chronic myelogenous leukemia and 
gastrointestinal stromal tumors); however, the genetic complexity and diversity of tumor cells, 
including the occurrence of cancer stem cells, have prevented molecular targeting from 
becoming universally successful.  Because the progression from  normal cell to  cancer cell 
involves numerous genetic mutations, targeting one or even several gene products may be 
ineffective.  Furthermore, many biological processes feature alternate pathways which can be up 
regulated, if needed, thus thwarting molecularly targeted therapies .[1] To overcome these 
obstacles, a successful cancer therapy has to combine several approaches.  Molecular targeting 
can be a viable component of this approach.  However, other approaches, such as stem cell 
delivery, hyperthermia, photodynamic therapy, and the design of multifunctional platforms that 
combine cancer diagnostics and treatment (theranostics) have not received full attention during 
the last decade. 
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    Melanoma 
Melanoma is cancerous disease caused by malignant melanocytes. Melanocytes are 
mainly present at the junction of epidermis and dermis in skin (Figure1.1). Melanocytes protect 
skin by synthesizing melanin pigment, which acts as a photoprotectant by absorbing UV 
radiation in sunlight. [2] Melanoma most commonly occurs in fair-skinned persons who have 
substantial sun exposure .[3] Melanoma can occur anywhere on the skin, and regional lymph 
nodes are the common sites for metastatsis .[4] Melanoma can also metastasize to soft tissue, 
lung, liver, and brain .[3] 
Figure 1.1 skin and melanoma 
 
http://www.sciencelearn.org.nz/contexts/you_me_and_uv/sci_media/images/cross_section_of_melanocytes 
 
Superficial spreading melanoma (SSM), nodular melanoma, acral lentiginous melanoma, 
and lentigo maligna melanoma are the major four types of melanomas.[2, 4] SSM comprises 
70% of all melanoma cases; it will be in radial growth phase (growing laterally) for 1-5 years 
before it starts the invading, vertical growth phase .[2, 4] Nodular melanoma comprises 15% to 
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30% all melanoma cases. Diagnosis of this melanoma is rather difficult because it lacks a radial 
growth phase and forms bulge-like tumors. It is usually a dark pigmented melanoma, but around 
5% of nodular melanomas lack pigmentation (amelanotic).[4] Acral lentiginous melanoma 
accounts for 5% of total melanoma cases. It predominantly occurs in dark pigmented persons, 
where it is found on hands and feet. Prognosis for this disease is worse than for other 
melanomas.[4]  Lentigo maligna melanoma (melanoma in situ) represents 5-15% of all 
melanoma cases and is mostly  located on the head and neck.[4] Based on the American cancer 
staging system(AJCC), primary tumor thickness (Breslow thickness), Clark levels ( depths of 
invasion), mitotic rate, tumor infiltrating lymphocytes, presence of ulceration, blood vessel and 
lymphatic invasion, and metastasis to lymph nodes are used as prognostic indicators in 
melanoma.[3] Subcutaneous invasion of melanoma is aggressive in tumor progression. Thus, in 
the following study, a B16-F10 mouse subcutaneous melanoma model was used. 
In its starting stages, melanoma is curable by surgical removal of melanoma tumors, but 
melanomas in the invasive and metastatic stages are much more difficult to cure.[5] Decarbazine 
is the most effective drug used for metastatic melanoma therapy; its responsive rate is 10-
20%.[5] There are other therapies using IL-2 and Hydroxy urea, but these two are not as 
effective as decarbazine, and there are several side effects with these therapies.[5] Melanoma is 
highly radioresistant, so radiotherapy to metastatic melanomas is a poor option.[4, 5] Therefore, 
novel therapies, which have the capacity to target melanoma with fewer side effects are 
necessary for metastatic melanoma therapy. 
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 Hyperthermia 
Temperature is one of the essential factors controlling cell survival. Changes in 
temperature can cause structural modifications; sometimes temperature itself is lethal to cells.  
Hyperthermia is a therapeutic approach to treat cancer treatment which uses higher temperatures 
which are lethal to cells .[6] Side effects caused by hyperthermia are significantly less than with 
other cancer treatments, because cancer cells are more sensitive to heat than healthy cells .[7] 
Hyperthermia is used in combination with other therapies that will improve the prognosis of 
cancer .[8] There are various types of hyperthermia based on the type of heat administration, 
such as hot water treatment, microwave, radiofrequency, ultra sound, and alternating magnetic 
field(AMF). In addition, the type of heat administration may vary: it will be either local, regional 
(at a specific place), or whole body hyperthermia.[6, 9, 10]  
Heat-induced changes in cells finally leads to either apoptosis or necrosis. [11] If cells are 
exposed to 40-43˚C, apoptosis results, while temperatures greater than 45˚C cause necrosis. [6] 
Lipid bilayer and membrane bound ATPases are the least thermally stable components and are 
most responsible for heat induced tissue necrosis. [11] Increases in temperature will also cause 
effects such as organelle changes, changes in protein conformation, heat shock protein (HSP) 
synthesis, and DNA and RNA degradation. [11] Cell death pathways involved in hyperthermia 
include mitochondria-mediated apoptosis, ER-mediated apoptotic pathways, and necrosis. [6, 11]  
Hyperthermia has an additive effect in combination therapies like chemotherapy and 
radiation therapy.[8] Exposure to heat increases blood flow to the tumors, which improves tissue 
oxygenation and increases radiosensitivity. [12] In the same way, drug concentration will be less 
in insufficiently perfused tumors; by increasing the blood flow, hyperthermia increases the drug 
concentration in tumors. [6] Chemotherapy combined with hyperthermia has showed improved 
results in tumor models by potentiating the drug effect. [6] To a certain point,hyperthermia 
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causes cells to overexpress HSPs, thus helping cells to recover from the temperature-induced 
damage by repairing proteins, synthesizing enzymes that prevent protein aggregation, and 
degrading severely damaged proteins. [13] But above a threshold temperature increase, 
inhibition of HSP synthesis occurs. [14]  HSPs released from necrotic cancer cells will have 
attached tumor specific antigens, which aids the innate and adaptive immune response against 
tumors. [15, 16] Antigen presenting cells (APCs) engulf HSP-protein complexes and subject 
them to antigen presentation (Srivastava 2002). In this way, hyperthermia causes specific 
immunity to tumors (immunotherapy combination with hyperthermia. [17-19] 
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    Magnetic Hyperthermia (MHT) 
Magnetic hyperthermia (MHT) became a major temperature-based treatment modality by 
using the magnetic properties of different compounds. The working principle behind MHT is that 
of exposing MNP to AMF. [20, 21] Two main things involved in MHT are the induction coil, 
which generates the AMF, and the MNPs, which generate heat when exposed to an AMF. The 
heat generation depends on the frequency, amplitude, and time exposed to AMF and on Curie 
temperature, Specific Absorption Rates (SAR), shape, size, dispersity (mono or poly), and type 
of MNPs. [22] 
MNPs create heat either by hystersis loss or Neel-Brownian relaxation when they are 
exposed to AMF. [23]  Which of these two processes happens depends on MNP size: if the 
particles are large (multi-domain particles), they will generate heat by hysteresis loss, while 
small size particles (single domain particles) generate heat by Neel –Brownian relaxations. [23] 
In multidomain particles hysteresis loss (due to the movement of domain walls) contributes to 
heating, in single domain particles Neel relaxation(random flipping of spin) and Brownian 
motion (rotation of entire particles) generates heat. [23, 24] The transition between the two 
mechanisms occurs between 5-12 nm for various materials, but it also varies with frequency 
[25]. 
MNPs vary with the magnetic component in the nanoparticles.  Among magnetic 
nanoparticles, superparamagnetic nanoparticles have more heat generating capacity (more 
SARs). [22, 26] Iron oxide MNPs are commonly used for MHT in animals because of their 
biodegradability, low toxicity, and higher SAR values.[27] Apart from MHT, MNPs have 
different uses in biomedicine like drug delivery, gene delivery,  stem cell tracking, MRI, 
biosensing, cell isolation, cellular proteomicsa.[28] 
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For MHT there are some factors of MNPs which must be considered before use in animals: 
solubility in an aqueous solvent, toxicity, heat distribution to surrounding healthy tissues, blood 
retention time, and targeting efficiency.[29] Less soluble particles (nanoparticle aggregates) will 
be easily engulfed by primary immune defensive cells in the vascular system.[29] To reduce 
aggregation and to increase solubility, MNPs can be coated by different coatings. These coatings 
will have some negative effect on the MNPs heat generating capacity. If the particles are 
themselves toxic to healthy cells, there will be more side effects. Several research groups have 
conducted preclinical studies in animal tumor models by directly injecting MNPs into tumors 
and observed tumor attenuation [30-33] Tumor specific targeting will be either passive or active. 
Passive targeting is achieved by the smaller MNPs via enhanced permeability and retention.[22, 
34] Tumor vasculature is  hyperpermeable compared to healthy tissue vasculatures, which helps 
the smaller MNPs accumulate in tumor interstitial spaces. [34]  The hydrophilic surfactant nature 
of MNPs also helps in passive targeting by allowing MNPs to avoid plasma protein absorption. 
[29] Active targeting is achieved by attaching tumor vasculature-specific and tumor cell-specific 
molecules onto the MNPs. [35] In this way MNPs will be taken up by tumors in higher numbers, 
thus limiting side effects to healthy tissue. [35] Some researchers have tried to target MNPs to 
tumors by attaching tumor-specific antibodies.[36] By using cancer targeting MNPs we can 
image the metastatic sites and we can treat them by using whole body MHT.  
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Porphyrin tethered stealth coated MNPs Iron(0)/Iron Oxide Core/Shell 
Magnetic Nanoparticles 
Localized hyperthermia is a powerful therapeutic modality.  When administered 
selectively, hyperthermia treatment can be very potent against many types of cancer because it is 
not based on the intake of drugs by cancer cells, but on the application of heat.  A multitude of 
heat-induced deviations from the “normal” metabolism of a cancer cell can eventually lead to 
apoptosis (programmed cell death).  Although many cancer types are slightly more susceptible to 
hyperthermia than healthy cells, the latter essentially share the same fate when heated. [29]  
Therefore, the development of methods to localize hyperthermia to cancer cells remains one of 
the challenges in this field.  This is important when attempting to treat solid tumors within the 
human body as well as for treatment of metastasizing cancers.   
(Bi)magnetic iron/iron oxide core/shell nanoparticles, synthesized by NanoScale 
Corporation for A/C (alternating current)-magnetic cancer therapy, exhibit superior properties in 
several areas: The small size (d<15 nm) of these stealth-protected Fe/Fe3O4 core/shell 
nanoparticles will permit passive tumor targeting from the bloodstream by using the EPR 
(enhanced permeation and retention) effect. [22] The strong paramagnetic iron core has higher 
magnetization moment and higher saturation magnetization permits MHT with lower 
concentrations and shorter AMF exposures. The Iron oxide shell surrounding it helps in imaging 
it through Magnetic Resonance Imaging (MRI). Dopamine on this shell acts as a good anchor for 
different ligands and increase the stability of MNPs against oxidation. Polyethylene glycol(PEG)  
ligands attached to this dopamine gives “stealth effect” to MNPs. Tumor cells selectively uptake 
porphyrins, which they need as prosthetic groups in their elevated sugar metabolism, via over-
expression of porphyrin receptors in their cell membranes. [37]  There is a strong positive 
correlation between the cell uptake of a variety of chemically defined, synthetic and natural 
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porphyrins and their octanol/water distribution coefficients. [38, 39]  These findings support the 
paradigm that there indeed exists a porphyrin uptake mechanism other than endocytosis in cancer 
cells.  The LDL (low-density lipoprotein) receptor, which is over-expressed in cancer cells, has 
the ability to take up porphyrins as well, either alone or simultaneously with other porphyrin 
receptors. 4-tetracarboxyphenyl porphyrin (TCPP) molecules are attached to the MNPs to 
increase the selective accumulation in tumor tissue and to increase the upatake of MNP by 
cancer cells. In this study detailed below, the intratumoral (IT) and intravenous (IV) core/shell 
porphyrin-tethered nanoparticle treatment followed by A/C exposure on melanoma growth in a 
mouse model are examined. 
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CHAPTER 2 - Porphyrin tethered stealth coated MNPs- in vitro 
studies on B16-F10 melanoma cells 
 Materials & Methods 
Cell lines  
B16-F10 melanoma cells were purchased from ATCC (Manassas, VA) and maintained in 
DMEM (Dulbecco’s Modified Eagle Medium) supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin in a humidified 37 C incubator at 5% CO2. 
Porphyrin tethered Stealth-Coated (Bi) Magnetic Fe/Fe3O4 Nanoparticles:  
Fe/Fe3O4-core/shell nanoparticles were synthesized by NanoScale Corporation and then 
coated with dopamine-anchored ligands.  The diameter of the inorganic cores was 5.4 1.1 nm.  
Note that the dopamine-anchored tetraethylene glycol ligand (I) and the TCPP-linked dopamine-
anchored tetraethylene glycol ligand (II) have been synthesized separately.  The binding of the 
ligands to the Fe3O4 layer was achieved in anhydrous tetrahydrofuran (THF) under argon; the 
molar ratio of ligands I/II was 100/4. We assume a statistical distribution of the ligands at the 
Fe3O4 surface. Assuming a Poisson distribution, 96.4 percent of the Fe/Fe3O4 NPs at the chosen 
ratio feature at least one chemically linked TCPP unit, which will act as “bait” for the B16-F10 
cancer cells.  The solubility of the organically coated Fe/Fe3O4 NPs was determined to be 0.35 
mg ml
-1  
 in water and the Specific Adsorption Rate (SAR) at the field conditions described here 
was 64+/-2 Wg
-1
 (Fe). 
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Determination of iron concentration in MNPs 
Iron concentration in MNPs was measured using the Ferrozine-based spectrophotometric 
iron estimation method. [40]  For this method, 50µl of MNPs were diluted to 1 ml with distilled 
water.  MNPs were then lysed by incubating for 2 hours at 65-70 ⁰C after the addition of 0.5 ml 
of 1.2M HCl and 0.2 ml of 2M ascorbic acid.  After incubation, 0.2 ml of reagent containing 
6.5mM Ferrozine, 13.1mM neocuproine, 2M ascorbic acid, and 5M ammonium acetate was 
added and incubated for 30 minutes at room temperature.  After 30 minutes, the optical density 
of the samples was measured using a UV-VIS spectrophotometer at 562 nm.  A standard curve 
was prepared using 0, 0.1, 0.2, 0.5, 1, 2, 5 μg/ml ferrous ammonium sulfate samples. Water with 
all other reagents is used as blank. 
Cytotoxicity of Magnetic Nanoparticles on B16-F10 cells 
Potential cytotoxic effects of MNPs were studied by incubating cells in differing 
concentrations of MNPs.  B16-F10 cells were incubated overnight with MNP amounts 
corresponding to 5, 10, 15, 20, and 25 μg/mL iron.  After incubation, the medium was removed, 
and the cells were washed twice with DMEM.  After collection by trypsinization, cells were 
counted via hemocytometer with Trypan blue staining.  This method also allows counting of 
non-viable cells, since only they allow the blue stain into the cell.  All experiments were run in 
triplicate. 
Prussian blue staining on MNP treated cells 
B16-F10 cells were incubated overnight with MNP-containing medium. After incubation 
cells were washed with DMEM two times, harvested with 0.1% trypsin-EDTA, and washed with 
PBS, followed by centrifugation to remove extra MNPs. These washed cells were replated; after 
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6 hours cells were fixed with 4% glutaraldehyde. Staining for iron content on these fixed cells 
was carried out using Perl’s Prussian blue staining kit (Polysciences, Inc., Warrington, PA).   
Statistical analysis 
Statistical analyses were performed by Macanova 4.12 (School of Statistics, University of 
Minnesota, Minneapolis, MN).  The means of the experimental groups were evaluated to confirm 
that they met the normality assumption.  To evaluate the significance of overall differences in 
live cell numbers between all MNP treated B16-F10 cells, statistical analysis was performed by 
analysis of variance (ANOVA).  A p-value less than 0.05 was considered as significant.  
Following significant ANOVA, post hoc analysis using least significance difference (LSD) was 
used for multiple comparisons.  Significance for post hoc testing was set at p < 0.05.   
Results and discussion 
MNP toxicity was tested after overnight incubation of B16-F10 cell cultures in 24-well 
plates with various MNP concentrations, as measured by iron concentration.  There was a dose-
dependent cytotoxicity of the MNPs.  B16-F10 cancer cell viability in the presence of varying 
concentrations of MNPs is shown in Figure 2.1.  The MNPs showed a pronounced cytotoxic 
effect on B16-F10 cells at >10 µg iron levels (p-value <0.05). Fixed, MNP-loaded cells are 
stained with Prussian blue staining (Figure2.2 A: control B16-F10 cells (without MNP); B: B16-
F10 cells incubated with MNP; C: MNP-incubated B16-F10 cells after Prussian blue staining 
(MNP are blue in color). 
Biocorrosion of these MNPs within the cancer cells (e.g. during endocytosis, within the 
cytoplasm, or in the cell organelles) causes the formation of free radicals by manifold Fenton-
type reactions.[41] Cationic iron (Fe+2, Fe+3) is essential for the cell cycle and for growth, but 
chelated and unbound iron can induce apoptosis by forming reactive oxygen species (ROS) .[41] 
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Figures and Tables 
Figure 2.1 
In vitro cell viability of B16-F10’s cultured in medium containing increasing 
concentrations of MNPs, as measured by iron concentration. *Statistically significant (p-value 
less than 0.05;two tail ANOVA)  
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Figure 2.2 
 
B16-F10 cells after overnight incubation with TCPP labeled MNP; A: control B16-F10 
cells(without MNP); B: B16-F10 cells incubated with MNP; C:MNP-incubated B16-F10 cells 
after Prussian blue staining (MNP are blue in color) 
A B
C
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CHAPTER 3 - Porphyrine tethered stealth coated MNPs-In vivo 
studies in a B16-F10 subcutaneous melanoma model 
Materials & Methods 
Cell lines and animals:  
B16-F10 melanoma cells were purchased from ATCC (Manassas, VA) and maintained in 
DMEM (Dulbecco’s Modified Eagle Medium) supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin in a humidified 37 C incubator at 5% CO2. 
Six-eight week old female C57/BL6 mice were purchased from Charles River 
Laboratories (Wilmington, MA).  Mice were maintained according to approved institutional 
IACUC guidelines in the Comparative Medicine Group Facility of Kansas State University.  All 
animal experiments were conducted according to these IACUC guidelines. 
Porphyrin-tethered Stealth-Coated (Bi) Magnetic Fe/Fe3O4 Nanoparticles 
Fe/Fe3O4-core/shell nanoparticles were synthesized by NanoScale Corporation and then 
coated with dopamine-anchored ligands. The diameter of the inorganic cores was 5.4 1.1 nm.  
Note that the dopamine-anchored tetraethylene glycol ligand (I) and the TCPP-linked dopamine-
anchored tetraethylene glycol ligand (II) have been synthesized separately.  The binding of the 
ligands to the Fe3O4 layer was achieved in anhydrous tetrahydrofuran (THF) under argon; the 
molar ratio of ligands I/II was 100/4.  We assume a statistical distribution of the ligands at the 
Fe3O4 surface. Assuming a Poisson distribution, 96.4 percent of the Fe/Fe3O4 NPs at the chosen 
ratio feature at least one chemically linked TCPP unit, which will act as “bait” for the B16-F10 
cancer cells.  The solubility of the organically coated Fe/Fe3O4 NPs was determined to 0.35 mg 
ml
-1
 in water and the SAR at the field conditions described here was 64+/-2 Wg
-1
 (Fe). 
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Magnetic Heating 
The nanoparticles used in these experiments are dominated by Néel relaxation due to the 
super paramagnetic nature of the iron(0) cores.  The hyperthermia apparatus used here has a 
“heavy duty” induction heater converted to allow measurement of the temperature change of a 
sample.  In the setup, a remote fiber optic probe (Neoptix) is used to monitor the temperature 
change.  The frequency is fixed (366 kHz, sine wave pattern); field amplitude is 5 kA/m.  The 
coil diameter is 1 inch, 4 turns continuously water-cooled.  For all in vivo experiments, the mice 
were placed into the induction coil using a specially designed Teflon supporter so that tumors 
were located exactly in the region of the AMF possessing the highest field density. 
Temperature measurements on mice 
MNPs containing 100 µg of iron in 100 µl of distilled water were injected into the rear 
limb muscle of one mouse and the leg was then exposed to AMF for 10 min.  A fiber optic 
temperature probe was inserted intramuscularly at the injection site, and the temperature increase 
was measured during AMF exposure.  At the same time, the body temperature was monitored 
with a separate temperature probe. 
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Intratumoral Hyperthermia 
Ten mice were transplanted subcutaneously into each rear limb above the stifle with 
1X10
6
 B16-F10 melanoma cells suspended in 50μL PBS.  120μL of saline were injected into 
melanomas on the left leg of all mice and 120 µl MNPs containing 1 mg Fe/mL were injected 
into right leg tumors of all mice in three injections on days 4, 5, 6 (total of 360 μg iron).  Both 
left (saline) and right (MNPs) leg tumors of five of the mice were exposed to AMF for 10 
minutes soon after the MNP injections.  Tumors on the remaining five mice were not exposed to 
AMF.  Based on this, there were 4 groups which tested the effects of MNPs with and without 
AMF and of AMF alone: Group 1, Intratumoral saline injection, not exposed to AMF (left legs 
of first five mice); Group 2, Intratumoral injection of saline, exposed to AMF (left legs of 
remaining five mice); Group 3, Intratumoral injection of MNPs, not exposed to AMF (right legs 
of first five mice); Group 4, Intratumoral injection of MNP, exposed to AMF (right legs of 
remaining five mice).  After three AMF exposures, tumor sizes were measured every day with a 
caliper on days 8 to 14, and tumor volume was calculated using the formula 0.5aXb
2
 (a=longest 
diameter; b=smaller diameter).  After 14 days mice were euthanized, tumors were excised, and 
tumor weights were measured. 
Intravenous administration of MNPs with AMF exposure  
On day 0, 3.5X10
5
 B16-F10 melanoma cells were injected subcutaneously into the right 
legs of 27 mice.  Mice were randomly divided into three groups: Group 1, IV MNPs, no AMF; 
Group II, IV MNPs, AMF; Group III, DMEM control, no AMF.  On days 6, 9, and 11 after 
tumor cell transplant, MNPs corresponding to 226 µg of iron were injected intravenously into 
each mouse in groups I and II.  On the same day, DMEM was injected intravenously into group 
III.  For group II, tumors were exposed to AMF for 10 minutes one day after each I.V. MNP 
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injection (total of three AMF treatments).  Tumor sizes were measured using a caliper on days 14 
and 18, and tumor volume was calculated as described above.  On day 18 all mice were 
euthanized, tumors were excised, and tumor weights were measured.  
Histological Analysis 
After euthanizing mice, lung, liver, and tumors were collected and snap frozen.  8-10 µm 
sections were made in a cryostat (Leitz Kryostat 1720).  Staining for iron content on these 
sections was carried out using Perl’s Prussian blue staining kit (Polysciences, Inc., Warrington, 
PA).  Apoptosis was evaluated using a DeadEnd Fluorometric TUNEL kit.  (Promega Corp., 
Madision, WI) following the manufacturer’s instructions. 
Statistical analysis  
Statistical analyses were performed by Macanova 4.12 (School of Statistics, University of 
Minnesota, Minneapolis, MN).  The means of the experimental groups were evaluated to confirm 
that they met the normality assumption.  To evaluate the significance of overall differences in 
tumor volumes and tumor weights between all in vivo groups, statistical analysis was performed 
by analysis of variance (ANOVA).  A p-value less than 0.1 was considered as significant.  
Following significant ANOVA, post hoc analysis using least significance difference (LSD) was 
used for multiple comparisons.  Significance for post hoc testing was set at p < 0.1.  All the 
tumor volumes and weight data were represented as mean +/- standard error (SE) on graphs.  
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Results 
Temperature measurements on mice after intramuscular MNPs injection  
We observed 11 °C temperature increase subcutaneously at the MNP injection site within 
10 minutes of AMF exposure.  There was no increase in core body temperature (Figure. 3.1).  
These data demonstrate specific magnetic hyperthermia.  However, we did not directly measure 
temperature change in tumors during experiments because the necessary skin opening for the 
probe caused leakage of the gelatinous melanoma tumor parenchyma, introducing increased 
potential variability in tumor volumes. 
Intratumoral Magnetic Hyperthermia 
After three AMF exposures, tumor sizes were measured from days 8 to 14; the 
comparison is shown in Figure. 3.2. We identified decreased tumor size in tumor-bearing mice 
treated with MNPs+AMF.  The tumors with MNPs+AMF showed a significant reduction in 
tumor volume at 8, 9, 11, & 14 days (p <0.1) compared to the saline treated group.  A decrease in 
size with only MNP treatment (no AMF) relative to the saline controls was also noted; however, 
this decrease was not significant.  Since earlier intramuscular injections and optical probe 
measurements revealed hyperthermia after AMF, the probable cause for the tumor attenuation 
shown here is local hyperthermia.  
Intravenously administered MNPs and AMF exposure 
Tumor-bearing mice with intravenously injected MNPs were exposed to AMF treatments 
three times and after 18 days were euthanized.  Tumor weights were obtained and compared to 
controls (Figure 3.4).  A significant decrease in tumor weight (p < 0.1) was observed in the 
intravenous MNPs+AMF group and was most likely due to heat generated from MNPs in 
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tumors, based on earlier optical probe experiments in anesthetized mice.  Some tumor weight 
decrease was also observed in intravenous MNPs without AMF treatment.  On days 14 and 18, 
tumor volumes were recorded and were attenuated in the mice with MNPs with AMF; however 
this was not significant (Figure 3.3).  After tumors were harvested and sectioned, MNPs in tumor 
sections and other tissues were identified as Prussian blue positive cells in tumor bearing mice 
intravenously injected with MNPs (Figure 3.5 A-D). 
Apoptosis assay  
Histological analysis after apoptosis assay with the modified TUNEL assay showed the 
most apoptotic positive cells in the intratumoral MNP +AMF treatments (Figure 3.6C), 
intermediate apoptosis levels in mice that received intravenous MNPs+AMF (Figure 3.6B), and 
the fewest apoptotic cells in the saline+AMF group (Figure 3.6A ). 
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Discussion 
The major finding of this study was that there is a significant decrease in tumor size after 
systemic (intravenous) administration of low (microgram iron content) amounts of the 
porphyrin-tethered MNPs and AMF exposure compared to tumors in animals given intravenous 
DMEM.  There are very few reports of tumor reduction after superparamagnetic nanoparticles 
are given this way, so the attainment of tumor attenuation here is a significant finding.  We have 
found the MNPs in the melanomas, indicating that the porphyrins attached to them facilitate 
MNP uptake.  As already discussed, cancer cells over-express porphyrin receptors, because they 
require more porphyrins as prosthetic groups in their elevated sugar metabolism than normal 
cells. [37]  Tumor localization of MNPs by urokinase plasminogen activator receptor (uPAR) is 
reported by Yang, Mao et al..[42]  
Intratumoral magnetic hyperthermia results showed that microgram amounts of iron 
delivered by the core-shell Fe/Fe3O4 nanoparticles caused an antitumor effect on melanoma with 
short-time AMF exposures (10 min.).  This is a clear improvement with respect to current 
protocols, which are defined by milligram amounts of MNPs and much longer exposure times, 
usually 30 minutes. [30]  We have also observed a trend toward decreased tumor size after MNP 
administration without AMF exposure.  This is not surprising, since our in vitro work indicated 
that the MNPs have a pronounced cytotoxic effect on B16-F10 cells.  Minamimura et al. gave 
intratumoral iron oxide MNP injections and noted that their MNPs alone exerted a noticeable 
anti-melanoma effect. [43]  In the study reported here, the effect of MNPs alone is most probably 
due to the biocorrosion of the MNPs and the subsequent release of iron(II) and iron(III) cations, 
which is known to cause cell damage via iron(II/III)-enhanced chemistry of reactive oxygen 
species (ROS). [44]  Since the MNPs remain active in vivo for 2-3 days, biocorrosion will most 
likely occur within the cancer cells (e.g. during endocytosis, within the cytoplasm, or in the cell 
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organelles).  Thus, we propose a two-pronged effect: magnetic hyperthermia and the additional 
generation of free radicals by manifold Fenton-type reactions.[44] 
It must be noted that there are significant amounts of iron in lungs and liver, as indicated 
by Prussian blue staining (Figure. 3.5).  Despite this widespread distribution of MNPs in vivo, we 
emphasize that we did not have any fatalities due to the blocking of arteries or exposure to AMF.  
This may be due to the fact that the AMF was only applied to the melanoma region, preventing 
unwanted hyperthermia in other tissues.  Minimal side effects after systemic administration of 
MNPs are corroborated by other work testing superparamagnetic NP for MRI capability and 
possible toxic effects.  Wiegand et al. showed that 250 or 500 nm ferrofluid given intravenously 
to normal rabbits resulted in normal serum iron and enzymes for liver and kidney function at 1-
72 hours after administration [45].  Kim et al. showed that silica over-coated magnetic 
nanoparticles of 50 nm size did not cause apparent toxicity or alter the blood-brain barrier in 
mice after four weeks [46]. 
The findings reported here indicate that ligand-modified MNPs given systemically or 
intratumorally at low concentrations can significantly attenuate subcutaneous B16-F10 tumors in 
mice after repetitive short AMF exposure.  Hence, it is possible to exploit upregulated porphyrin 
uptake by cancer cells to facilitate targeted delivery of core/shell bimagnetic nanoparticles.  After 
exposure to an AMF, which itself causes no harm, localized hyperthermia of cancer tissue results 
in attenuation of the tumor without the undesirable side effects associated with traditional 
chemotherapy.  This approach also circumvents failure of molecularly-targeted approaches due 
to redundant systems and failure of chemotherapeutic approaches due to cancer cell multidrug 
resistance.  Furthermore, AMF treatment is augmented by the release of iron within the tumor 
regions due to biocorrosion, increasing the intratumoral concentration of cytotoxic reactive 
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oxygen species.  Thus, localized hyperthermia after systemic administration of porphyrin labeled 
stealth MNPs may hold promise for future clinical therapy of melanomas. 
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Figures and Tables 
Figure 3.1 
Graph depicting temperature change at MNP injection site and in body core during AMF 
exposure, measured with a fiber optic temperature probe.  
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Figure 3.2 
Effect on tumor burden of intratumoral injection of MNPs followed by alternating 
magnetic field (AMF) treatments.  Graph depicting average tumor volumes over time of B16-
F10 tumor bearing mice which were later injected with either saline or MNP intratumorally and 
with or without AMF treatments.  *Statistically significant (p-value less than 0.1). 
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Figure 3.3 
Tumor volume comparison of intravenous MNP administration and AMF exposure group 
with intravenous DMEM (placebo) and intravenous MNP without AMF exposure groups on day 
14 and day 18. (Not statistically significant) 
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Figure 3.4 
Effect of intravenous injection of MNP and AMF on tumor weight.  *Statistically 
significant (p-value less than 0.1) between control and IV MNP+AMF groups. 
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Figure 3.5 
Prussian blue staining on tissue sections after the in vivo experiment.  A-C: IV MNP + 
AMF in tumor, lung, and liver, respectively D: IT MNP+AMF tumor (Scale bar =100 μm). 
 
A B
C D
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Figure 3.6 
Green fluorescence indicates apoptosis positive and blue is DAPI counterstaining. A-C: 
Apoptosis assay pictures.  A: Control tumor section.  B: Tumor section with intravenous MNP 
administration followed by AMF.  C: Tumor section with intratumoral MNP administration 
followed by AMF.  (Scale bar =100 μm) 
A B
C
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